# Protocol for the development and validation of a Rheumatoid Arthritis Prediction moDel using primary care health records (RAPID)

Ben Hammond<sup>1</sup>, Aliaksandra Baranskaya<sup>2</sup>, Nicola Adderley<sup>1,3</sup>, Dawit Zemedikun<sup>1,4</sup>, Alexander d'Elia<sup>5</sup>, Marie Falahee<sup>2,3</sup>, Christian Mallen<sup>6</sup>, Elspeth Insch<sup>2</sup>, Joht Singh Chandan<sup>1,3</sup>, Krishnarajah Nirantharakumar<sup>1,3</sup>, Kym Snell\*<sup>1,3</sup>, Karim Raza\*<sup>2,3,6</sup>

### **Abstract**

#### **Background**

Rheumatoid Arthritis (RA) is a chronic rheumatological condition which causes inflammation of both the joint lining and extra-articular sites. It affects around 1% of the UK population and, if not properly treated, can lead joint damage, disability, and significant socioeconomic burden. The risk of long-term damage is reduced if treatment is started in an early disease stage with treatment in the first 3 months being associated with significantly improved clinical outcomes. However, treatment is often delayed due to long referral waits and challenges in identifying early RA in primary care. We plan to use large primary care datasets to develop and validate an RA risk prediction model for use in primary care, with the aim to provide an additional mechanism for early diagnosis and referral for treatment.

#### Methods

We identified candidate predictors from literature review, expert clinical opinion, and patient research partner input. Using coded primary care data held in Clinical Practice Research Datalink (CPRD) Aurum, we will use a time to event Cox proportional hazards model to develop a 1-year risk prediction model for RA. This will be validated first in CPRD GOLD and then independently in the Secure Anonymised Information Linkage dataset. We will also conduct a sensitivity analysis for the same model at 2–5-year risk, with a secondary outcome of RA and initiation of a disease modifying drug, and with the addition of laboratory test results as candidate predictors.

#### **Discussion**

The resulting risk prediction model may provide an additional mechanism to distinguish early RA in primary care and reduce treatment delays through earlier referral.

<sup>&</sup>lt;sup>1</sup>Institute of Applied Health Research, University of Birmingham, Birmingham, UK <sup>2</sup>Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

<sup>&</sup>lt;sup>3</sup>NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>&</sup>lt;sup>4</sup>Cardiovascular Epidemiology Research Centre, School of Population and Global Health, The University of Western Australia, Perth, WA, Australia

<sup>&</sup>lt;sup>5</sup>Department of Public Health Policy and Systems, Institute of Population Health, University of Liverpool, UK

<sup>&</sup>lt;sup>6</sup>Faculty of Medicine and Health Sciences, Keele University, UK

<sup>&</sup>lt;sup>7</sup>Department of Rheumatology, Bronglais Hospital, Hywel Dda University Health Board, Aberystwyth, UK

<sup>\*</sup>Joint senior author

# Introduction

Rheumatoid Arthritis (RA) is a chronic rheumatological condition associated with both inflammation of the joint lining as well as wider extra-articular inflammation. (1,2) It currently affects approximately 1% of the UK population (3) and can present with a variety of symptoms including joint pain, stiffness swelling and fatigue. (4) If it is not treated effectively, it can lead to long term complications such as joint damage and disability, contribute to additional co-morbidities such as cardiovascular disease, and create a significant socioeconomic burden due to factors such as patients being unable to work. (5) However, very early treatment of rheumatoid arthritis (RA) has been shown to bring significant benefits, with treatment in the first 3 months of the condition being especially important. (6,7) Prior research has established that treatment within this period can lead to significantly improved clinical outcomes such as reduced joint damage, lower radiographic progression, and the potential for increased likelihood of sustained remission. (6,7)

Despite this, identifying patients in this early disease stage is challenging and many do not receive treatment within the recommended timeframe. (8) Musculoskeletal problems, such as back pain and osteoarthritis, present commonly in primary care (9) and distinguishing early RA symptoms from other musculoskeletal symptoms can be challenging for non-specialists. (10,11) Delays to early treatment are further confounded by long referral waiting times and a lack of fast-track pathways, with the 2021-2022 National Early Inflammatory Arthritis Audit finding that only 42% of patients received specialist review within 3 weeks of referral. (12)

Prediction models have been developed to predict adverse outcomes, treatment, and clinical response in RA patients, (13-19) however, to the best of our knowledge, no prediction models have yet utilised large primary care datasets to assess RA risk in a primary care setting. Such a prediction model could aid early diagnosis by flagging patients who are at a higher risk of having the condition as well as providing an additional mechanism to distinguish possible RA patients from those with similarly presenting common musculoskeletal pathologies.

Earlier work has established the presence of signs and symptoms associated with RA coded in large primary care database of electronic healthcare records, specifically Clinical Practice Research Datalink (CPRD). (20) Thus, we hypothesise that a prediction model trained on large, representative, primary care EHR datasets could provide better detection of early RA in primary care, better decision support for early referral to rheumatology specialist care and reduced treatment delay.

# **Objectives**

- Develop and internally validate a prediction model for new diagnosis of RA in CPRD Aurum:
  - a. Using coded clinical diagnosis, symptoms, medications, and baseline patient characteristics as candidate predictors
  - b. Additionally using laboratory test results
- ii. Externally validate the resulting prediction models in the CPRD GOLD and SAIL databases.
- iii. Compare the performance of the models internally and externally using measures of calibration, discrimination, and clinical utility.

# Research Design and Methods

#### Data sources

Routinely collected primary care data from three large anonymised electronic healthcare record (EHR) databases will be utilised. The first, CPRD Aurum, will be used to develop the models. CPRD Gold will then be used for initial external validation and SAIL will be used for independent external validation. These databases are described in further detail below:

- 1. Clinical Practice Research Datalink (CPRD) is an anonymised store of primary care records available for use in research. (21) It contains data on diagnosis, symptoms, medication, and laboratory test results as well as wider sociodemographic descriptors and baseline characteristics. (21) It is split into two databases, CPRD Aurum and Gold. CPRD Aurum includes practices using the EMIS system and primarily consists of practices in England and Northern Ireland and contains 16,011,762 active patients and 19.77% of UK general practices (as of December 2023). (22) CPRD GOLD includes those using the Vision software and mostly contains practices in Scotland. This provides data from an additional 2,967,792 patients covering another 4.55% of general practices. (23)
- 2. Secure Anonymised Information Linkage (SAIL) is an anonymised, Wales wide research available dataset containing EHR data representing 80% of the Welsh population, containing records of over 5 million patients who have used public services in Wales. (24- 26)

# Target Population

This study will take a population level approach, specifically focussing on primary care. Patients are eligible for inclusion if they are aged 18 or over at index date (defined below),

do not have a record of RA prior to index date and were registered with a GP practice contributing to the relevant database between 1<sup>st</sup> January 2000 and 31<sup>st</sup> December 2022. Additionally, patients must be registered at the practice for at least 12 months before being eligible to contribute data.

The aim of the prediction models is to aid referral and diagnosis of RA earlier in the disease pathway and so it is intended for use with individuals consulting with early symptoms of RA. Therefore, entry into the cohort will require patients to report at least one musculoskeletal trigger symptom, which are outlined in further detail below.

The index date will be the point a patient reports one of the trigger symptoms. Additional clinical codes reported 3 months after index will also be included as baseline values as it is likely there will be a delay for some additional symptoms to be recorded in the routine dataset. Follow up will be from the defined index date to the earliest of date of outcome, date of transfer to another practice, practice stops contributing to the dataset, study end date or death date.

## Study Outcome

The study outcome is defined as the earliest recorded diagnosis of rheumatoid arthritis occurring after the index date. This will be detected using a combination of SNOMED and Read codes (clinical coding systems used in primary care electronic healthcare systems in the NHS (27)) with the primary outcome being presence of a clinical code in the patient record indicating RA. A secondary outcome of a clinical code of RA as well as initiation of a disease-modifying antirheumatic drug (DMARD) will also be investigated. The lists of relevant codes defining the outcome will be reviewed by clinical members of the research team to ensure they accurately represent the outcome of interest.

# Clinical Predictor Variables

Initial work has selected candidate predictors through a multi-stage process. In the first step, a longlist of predictors of RA were identified from a literature review, clinical expert opinion from both General Practitioners and Rheumatologists, and patient research partner input. Predictors will be identified from codes contained in the patient record data so lists of SNOMED and Read codes have been created for each included predictor within the longlist. This resulted in a high number of predictors which could have reduced model stability and useability of any subsequent web calculator tools.

As a result, a second review was undertaken to reduce predictor numbers whilst retaining the most relevant clinical factors. To inform this, descriptive statistics were initially reported for each of the longlisted predictors. Non-musculoskeletal symptom codes with a clear clinical grouping will be first grouped into one predictor. Predictors with very low frequencies will then be grouped with similar codes if they share a clinically plausible link. These groups will be reviewed by clinician experts and any disagreements will be resolved by KR, a subject expert.

The candidate predictors which have been selected for use in the model development are reported in table 2. To ensure musculoskeletal and acute symptoms are related to a possible RA diagnosis, some predictor values are limited to only those reported up to 2 years prior to the index date. These were selected by clinical consensus and are also outlined in table 2. For patient characteristics and chronic conditions, no time limit was applied.

A subset of these predictors, reported in table 1 below, will additionally be used to define entry into the cohort. Predictors are eligible to be selected for this if they had a strong clinical association with RA, with a specific focus on selecting cardinal musculoskeletal symptoms of the condition. The initial list of predictors was presented to three clinicians, covering rheumatology and primary care, who independently selected the clinical symptoms they believed to have strong associations with RA that should trigger the model. Any conflicting results are resolved through a discussion with the study team, including KR who is a subject expert in RA. This process resulted in the trigger symptoms shown in Table 1, being selected as an additional entry criterion to the cohort.

Table 1: Symptoms that define entry into the cohort.

Symptom	Description	as n
Synovitis	A reported symptom of synovitis.	et cer
Arthralgia	A reported symptom of arthralgia or related synonyms.	tified
Stiffness	A reported symptom of generalised stiffness or joint specific stiffness. Grouped due to low frequency of joint spec stiffness.	fic peer r
Swelling	A reported symptom of generalised swelling or joint specific swelling. Grouped due to low frequency of joint speci- stiffness.	eview) is signade av
Palindromic RA	A record relating to palindromic RA.	the au
Tendinitis	A reported symptom of tendinitis	thor/fue unde
Carpal Tunnel Syndrome	A reported symptom of carpel tunnel syndrome	nder,
Ankle Symptom (other or not specified)	Ankle related pathologies not listed below, or ankle mentioned but specific condition not otherwise specified.	who h
Ankle Pain	A reported symptom of pain specifically linked to the ankle.	nas gra
Ankle Arthritis	A reported symptom of a form of ankle arthritis not exclusive to rheumatoid arthritis.	hor/funder, who has granted under a CC-BY-NC-ND 4.01
Elbow Symptom (other or not specified)	Elbow related pathologies not listed below, or elbow mentioned but specific condition not otherwise specified.	medRxiv a
Elbow Pain	A reported symptom of pain specifically linked to the elbow.	xiv a I
Elbow Arthritis	A reported symptom of a form of elbow arthritis not exclusive to rheumatoid arthritis.	license
Foot Symptom (other or not specified)	Foot related pathologies not listed below, or foot mentioned but specific condition not otherwise specified.	to di
Foot Pain	A reported symptom of pain specifically linked to the foot.	splay t
Foot Arthritis	A reported symptom of a form of foot arthritis not exclusive to rheumatoid arthritis.	cense to display the preprint license.
Jaw Symptom (other or not specified)	Jaw related pathologies not listed below, or jaw mentioned but specific condition not otherwise specified.	orint in

medRxiv preprint doi: https://doi.org/10.1101/2024.04.09.24305328; this version posted April 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

		⋾
		nedRxi (whic
Jaw Pain	A reported symptom of pain specifically linked to the jaw.	medRxiv preprint doi: https: (which was not certified
Knee Symptom (other or not specified)	Knee related pathologies not listed below, or knee mentioned but specific condition not otherwise specified.	rint do
Knee Pain	A reported symptom of pain specifically linked to the knee.	i. https ertified
Knee Arthritis	A reported symptom of a form of knee arthritis not exclusive to rheumatoid arthritis.	s://doi.o
Shoulder Symptom (other or not specified)	Shoulder related pathologies not listed below, or shoulder mentioned but specific condition not otherwise specified	d <del>, g</del> 70/10
Shoulder Pain	A reported symptom of pain specifically linked to the shoulder.	1101/ /iew) made
Shoulder Arthritis	A reported symptom of a form of shoulder arthritis not exclusive to rheumatoid arthritis.	2024 s the avail
Wrist Symptom (other or not specified)	Wrist related pathologies not listed below, or wrist mentioned but specific condition not otherwise specified.	.04.09.243053 author/funde able under a
Wrist Pain	A reported symptom of pain specifically linked to the wrist.	24305 /funde der a
Wrist Arthritis	A reported symptom of a form of wrist arthritis not exclusive to rheumatoid arthritis.	328; tl er, who
Neck Other	Neck related pathologies not listed below, or neck mentioned but specific condition not otherwise specified.	328; this version posted April ir, who has granted medRxiv CC-BY-NC-ND 4.D Internation
Neck Pain	A reported symptom of pain specifically linked to the neck.	sion p grante ND 4.
Hand Other	Hand related pathologies not listed below, or hand mentioned but specific condition not otherwise specified.	osted d med <mark>) Inter</mark>
Hand Pain	A reported symptom of pain specifically linked to the hand.	
Hand Arthritis	A reported symptom of a form of hand arthritis not exclusive to rheumatoid arthritis.	12, 20 a licental al lice
Hip Other	Hip related pathologies not listed below, or hip mentioned but specific condition not otherwise specified.	24. Th se to d
Hip Pain	A reported symptom of pain specifically linked to the hip.	e copy lisplay
Hip Arthritis	A reported symptom of a form of hip arthritis not exclusive to rheumatoid arthritis.	right h
		12, 2024. The copyright holder for this preprint a license to display the preprint in perpetuity.
		for thi in per
		s prep petuity
		rint '.

medRxiv preprint doi: https://doi.org/10.1101/2024.04.09.24305328; this version posted April 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 2: List of predictors and their period of eligibility for inclusion.

Final Code List Name	Longlist Code List Name	Description	Timeline
	Musculoskeletal Sy	mptom or Diagnosis	
Muscle Pain and Cramps	Muscle Pain and Cramps	Record of either muscle pain or cramps	2-Years
	Stiffness		
	Ankle Stiffness		
	Elbow Stiffness		
Γ	Foot Stiffness		
Γ	Jaw Stiffness	Record of generalised stiffness or joint specific	
Stiffness	Knee Stiffness	stiffness. Grouped due to low frequency of joint specific	2-Years
Γ	Shoulder Stiffness	stiffness.	
	Wrist Stiffness		
	Neck Stiffness		
	Hand Stiffness		
Γ	Hip Stiffness		
	Ankle Swelling		
	Elbow Swelling		
	Foot Swelling		
	Jaw Inflammation	Depart of generalized awalling or joint apositic awalling	
Swelling	Knee Swelling	Record of generalised swelling or joint specific swelling.  Grouped due to low frequency of joint specific stiffness.	2-Years
	Shoulder Swelling	Grouped due to low frequency of joint specific stiffless.	
	Wrist Swelling		
	Hand Swelling		
	Hip Swelling		
Tendinitis	Tendinitis	Record of tendinitis	2-Years
Synovitis	Synovitis	Record of synovitis	2-Years
Altered Sensation	Altered Sensation	Record of altered sensation or related synonyms.	2-Years
Arthralgia	Arthralgia	Record of arthralgia or related synonyms.	2-Years

Carpal Tunnel Syndrome	Capel Tunnel Syndrome	Record of carpal tunnel syndrome	2-Years
Family History of RA	Family History of RA	Record of family history of RA.	Lifetime
	Ankle Abnormal Finding but Not Otherwise Specified		
	Ankle Enthesopathy		
	Ankle Ganglion		
	Ankle Impingement	Ankle related pathologies not listed below, or ankle	
Ankle Other	Ankle Sprain	mentioned but specific condition not otherwise	2-Years
	Ankle Tendinitis	specified.	
	Ankle Normal Finding but Not Otherwise Specified		
	Ankle Mentioned but Not Otherwise Specified (Neutral)		
Ankle Pain	Ankle Pain	Record of pain specifically linked to the ankle.	2-Years
Ankle Arthritis	Ankle Arthritis	Record of a form of ankle arthritis not exclusive to rheumatoid arthritis.	2-Years
	Elbow Ganglion	Elbow related pathologies not listed below, or elbow mentioned but specific condition not otherwise specified.	
	Elbow Abnormal Finding but Not Otherwise Specified		
	Elbow Bursitis		
	Elbow Cubital Tunnel Syndrome		
Elbow Other	Elbow Enthesopathy		2-Years
Libow Other	Elbow Epicondylitis		2-16ais
	Elbow Sprain		
	Elbow Mentioned but Not Otherwise		
	Specified (Neutral)		
	Elbow Normal Finding but Not Otherwise		
	Specified		
Elbow Pain	Elbow Pain	Record of pain specifically linked to the elbow.	2-Years
Elbow Arthritis	Elbow Arthritis	Record of a form of elbow arthritis not exclusive to rheumatoid arthritis.	2-Years

Foot Other	Foot Bursitis  Foot Enthesopathy  Foot Fasciitis  Foot Ganglion  Foot Morton's  Foot Sprain  Foot Tendinitis  Foot Tarsal Tunnel Syndrome  Foot Mentioned but Not Otherwise  Specified (Neutral)  Foot Normal Finding but Not Otherwise  Specified  Foot Abnormal Finding but Not Otherwise  Specified	Foot related pathologies not listed below, or foot mentioned but specific condition not otherwise specified.	2-Years
Foot Pain	Foot Pain	Record of pain specifically linked to the foot.	2-Years
Foot Arthritis	Foot Arthritis	Record of a form of foot arthritis not exclusive to rheumatoid arthritis.	2-Years
Jaw Other	Jaw Abnormal Finding but Not Otherwise Specified Jaw Disorder Jaw Temporomandibular Joint Dysfunction Jaw Mentioned but Not Otherwise Specified (Neutral) Jaw Normal Finding but Not Otherwise Specified	Jaw related pathologies not listed below, or jaw mentioned but specific condition not otherwise specified.	2-Years
Jaw Pain	Jaw Pain	Record of pain specifically linked to the jaw.	2-Years
Knee Other	Knee Abnormal Finding but Not Otherwise Specified Knee Bursitis Knee Enthesopathy Knee Iliofemoral	Knee related pathologies not listed below, or knee mentioned but specific condition not otherwise specified.	2-Years

0 V	
0.14	
0.1/	
0.17	
2-Years	
2-Years	
	2-Years
	2-16ais
2-Years	
2-Years	
2-Years	
2-1ears	
2 2	

	Wrist Enthesopathy		
	Wrist Sprains		
	Wrist Tenosynovitis		
	Wrist Ganglion		
	Wrist Mentioned but Not Otherwise		
	Specified (Neutral)		
	Wrist Normal Finding but Not Otherwise		
	Specified		
Wrist Pain	Wrist Pain	Record of pain specifically linked to the wrist.	2-Years
Wrist Arthritis	Wrist Arthritis	Record of a form of wrist arthritis not exclusive to rheumatoid arthritis.	2-Years
	Neck Abnormal Finding but Not Otherwise Specified	Neck related pathologies not listed below, or neck mentioned but specific condition not otherwise specified.	
	Neck Mentioned but Not Otherwise		
Neck Other	Specified (Neutral)		2-Years
Neck Other	Neck Pathology Reported		2-16ais
	Neck Sprain	specified.	
	Neck Normal Finding but Not Otherwise Specified		
Neck Pain	Neck Pain	Record of pain specifically linked to the neck.	2-Years
	Hand Ganglion		
	Hand Abnormal Finding but Not Otherwise Specified	Hand related pathologies not listed below, or hand mentioned but specific condition not otherwise	
	Hand Bursitis		
	Hand Mentioned but Not Otherwise		
Hand Other	Specified		2-Years
	Hand Sprain	specified.	
	Hand Tendinitis		
	Make A Fist		
	Hand Mentioned but Not Otherwise Specified (Neutral)		

	Hand Normal Finding but Not Otherwise Specified		
Hand Pain	Hand Pain	Record of pain specifically linked to the hand.	2-Years
Hand Arthritis	Hand Arthritis	Record of a form of hand arthritis not exclusive to rheumatoid arthritis.	2-Years
	Hip Ganglion		
	Hip Abnormal Finding but Not Otherwise		
	Specified		
	Hip Bursitis		
	Hip Enthesopathy	His related pathologica not listed helow, or his	
Hip Other	Hip Impingement	Hip related pathologies not listed below, or hip mentioned but specific condition not otherwise	2-Years
Tilp Other	Hip Irritable	specified.	2-16ais
	Hip Sprain	specilieu.	
	Hip Mentioned but Not Otherwise Specified		
	(Neutral)		
	Hip Normal Finding but Not Otherwise		
	Specified		
Hip Pain	Hip Pain	Record of pain specifically linked to the hip.	2-Years
Hip Arthritis	Hip Arthritis	Record of a form of hip arthritis not exclusive to rheumatoid arthritis.	2-Years
	Non-Musculoskeletal	Clinical Diagnosis	
Vival Infantion	Record of EBV Infection	Infantion with EDV or non-reviews	2-Years
Viral Infection	Record of Parvovirus Infection	Infection with EBV or parvovirus	2-Years
	Record of IHD		
Heart Disease	Record of an MI	Record of an MI or heart failure	Lifetime
	Record of Heart Failure		
	Ischaemic Stroke		
Stroke	Haemorrhagic Stroke	Record of stroke	Lifetime
	Unspecified Stroke		
Allergies	Allergies	Record of allergies	Lifetime

	Asthma		
Atopic Conditions	Atopic Eczema	Record of atopic asthma, eczema, or allergic rhinitis	Lifetime
	Allergic Rhinitis		
	Depression		
Mental Health Condition	Anxiety	Record of anxiety, depression, or PTSD	Lifetime
	PTSD		
IBD	Crohn's Disease	Record of Crohn's or Ulcerative Colitis	Lifetime
IDD	Ulcerative Colitis	Record of Croffins of Olcerative Collis	Liletime
Embolism	Pulmonary Embolism	Record of either venous or pulmonary	Lifetime
LITIDOIISITI	Venous thromboembolism	thromboembolism	Lifetiffe
Lung Pathology	Interstitial Lung Disease	Pagerd of COPD or interstitial lung disease	Lifetime
Lung Pathology	COPD	Record of COPD or interstitial lung disease	Liletime
Type 1 DM	Type 1 Diabetes Mellitus	Record of Type 1 diabetes mellites	Lifetime
Type 2 DM	Type 2 Diabetes Mellitus	Record of Type 1 diabetes mellites	Lifetime
Autoimmune Thyroid	Autoimmune Thyroid	Record of autoimmune thyroid disease	Lifetime
Endometriosis	Endometriosis	Record of endometriosis	Lifetime
Early Menopause	Early Menopause	Record of early menopause	Lifetime
Hepatitis	Hepatitis C	Record of hepatitis	Lifetime
Pemphigus	Pemphigus	Record of pemphigus	lifetime
Periodontitis	Peritonitis	Record of periodontitis	Lifetime
Pregnancy	Pregnancy	Record of either pregnancy or pregnancy exclusive condition/ symptom.	Lifetime
Sleep Problems	Sleep Problems	Record suggesting insomnia or related synonyms	2-Years
Stress	Stress	Record suggesting high stress levels	Lifetime
	Other Clinic	al Findings	
Weakness	Weakness	Record of weakness or related synonyms.	2-Years
Falls	Falls	Record of falls	2-Years
Fatigue	Fatigue	Record of fatigue, tiredness, or related synonyms	2-Years
Weight Loss	Weight loss	Record of unexpected weight loss.	2-Years
Medication Use			

	Topical NSAID Use		
NSAID Use	Topical NSAID Derivatives	Use of NSAID	2-Years
	Oral NSAID		
Opioid Use	Weak Opioid Use	Use of opioid	2-Years
Opiola Ose	Strong Opioid Use	Ose of opioid	2-16015
Oral Corticosteroid Use	Systemic Oral corticosteroid Use	Use of oral corticosteroids	2-Years
Contraceptives	Progesterone Only Contraceptive Pill use	Use of either combined or progesterone only pill	Lifetime
Contraceptives	Combined oral contraceptive pill use	Ose of either combined of progesterone only pill	Liletime
	SSRI Use		
Anti-Depressant Use	Amitriptyline Use	Use of an antidepressant	2-Years
	SNRI use		
Hormone Replacement Therapy	Hormone Replacement Therapy	Use of hormone replacement therapy	Lifetime
Statins	Statins	Use of statins	Lifetime
Vitamin D use	Vitamin D use	Use of vitamin D	Lifetime
	Laborato	ry Tests	
Haemoglobin	Haemoglobin	Serum haemoglobin count	2-Years
Platelet Count	Platelet Count	Serum platelet count	2-Years
Erythrocyte Sedimentation Rate	Erythrocyte Sedimentation Rate	Erythrocyte Sedimentation Rate	2-Years
C-Reactive Protein	C-Reactive Protein	Serum CRP level	2-Years
HbA1C	HbA1C	Serum HbA1C level	2-Years
Rheumatoid Factor	Rheumatoid Factor	Serum Rheumatoid Factor Level	2-Years
eGFR	eGFR	eGFR rate recorded in record	2-Years
Vitamin D Level	Vitamin D Level	Serum vitamin D level	2-Years
Anti-Cyclic Citrullinated Peptide	Anti-Cyclic Citrullinated Peptide	Serum anti-CCP level	2-Years
	Baseline Cha	aracteristics	

Age	Age	Participant age at baseline	Lifetime
Sex	Sex	Patient sex	Lifetime
		Patient ethnicity (White, Black, Asian, Other and Mixed,	
Ethnicity	Ethnicity	Missing)	Lifetime
BMI	BMI	Patient BMI as continuous value	Lifetime
Index of Multiple			
Deprivation Score	Index of Multiple Deprivation Score	Participant IMD score at postcode level	Lifetime
Smoking Status	Smoking Status	Current patient tobacco smoking status (Smoker, Ex- Smoker, Non-Smoker)	Lifetime
Alcohol Misuse	Alcohol Misuse	Record of alcohol misuse or excess alcohol use.	Lifetime
High levels of Physical Activity	High levels of physical activity	Record reporting high levels of physical activity or exercise.	Lifetime
Low levels of activity	Low levels of physical activity	Record reporting low levels of physical activity or exercise	Lifetime

# Statistical analysis

# **Descriptive Statistics**

To summarise the cohorts for both the model training and validations, we will report descriptive statistics. Categorical and binary variables will be summarised using frequencies and percentages. Continuous variables will be summarised by mean and standard deviation when normally distributed or median and interquartile range when not. A baseline table describing the cohort characteristics, including stratifying by those who did and did not develop the outcome of interest within the study period, will also be reported.

## Missing data

The degree of missing data for each candidate predictor will be investigated prior to model development. For each predictor, descriptive statistics will be reported as described above. Several separate approaches will then be utilised to handle missing data depending on missingness and clinical importance. In a similar approach as reported in other EHR based prediction models (28), the absence of data relating to a clinical condition or symptom recorded in a binary format will be presumed to mean that the condition is not present for that participant. For categorical predictors (e.g. smoking status and ethnicity) a separate missing category will be created. For continuous predictors, suitable imputation strategies will be investigated as, due to the nature of EHR, missingness is likely informative for these variables and this will need to be considered within any imputation approach.

# Model Development

Predictor selection will be carried out using multivariable fractional polynomial models. As part of this, we will carry out backwards elimination with predictors not meeting the 0.157 level of significance being removed from the model. Continuous variables will be kept as continuous and modelled non-linearly using fractional polynomials when the fit is improved. Clinically significant variables, decided by clinical expert opinion, will be forced into the model regardless of statistical significance. All models will utilise Cox Proportional Hazards Regression. The proportional hazards assumptions will be checked using 'log-log' plots and an extension to time dependent effects will be considered if necessary.

#### Internal Validation

Due to the large dataset, overfitting and optimism are expected to be very small (see sample size section below). Bootstrapping would be computationally intensive and only provide small adjustments. As such, a heuristic uniform shrinkage factor will be calculated and used to adjust for any optimism present in the final model if necessary.

## Model Performance

Model fit will be appraised using Cox-Snell and Nagelkerke R-squared. Model performance will be evaluated using measures of discrimination and calibration. Discrimination will be evaluated using Harrell's C index and assessed over the whole follow-up period as well as looking at time-dependent C indexes. Calibration will be evaluated by plotting predicted and observed probability of the outcome (calibration plot), ratio of observed and expected outcome (calibration in the large) and the calibration slope. Clinical utility will be assessed using decision curve analysis, showing the net benefit of the model across a range of threshold probabilities. All performance measures will be calculated at the primary point of follow up of 1 year.

## Sensitivity Analysis

Model performance will be analysed using both the primary outcome definition of RA, defined by an RA code, as well as by a sensitivity analysis including the secondary outcome of RA defined by both an RA code and evidence of starting a DMARD. Model performance will also be evaluated at 2–5-year risk through adjusting the baseline survival value, in addition to the primary follow up of 1 year.

## Sample Size for Development

Utilising an estimated event rate of 0.0017, a target shrinkage factor of 0.9, 95 predictor parameters, and an R<sup>2</sup> value of 0.15 (default), we estimated that, for predictions at 1 year after the index date, the minimum sample size required would be 213,275 patients with 363 outcome events. Due to CPRD Aurum containing 16,011,762 active patients (22), we believe we will very likely exceed this requirement and anticipate low overfitting. If this is not the case, we will reduce the number of model parameters to ensure the expected shrinkage is no less than 0.9.

#### External Validation

External validation of the final model will be carried out in two separate datasets. First, the model will be externally validated in CPRD GOLD by the University of Birmingham research group who will also be developing the model. Secondly, an independent group at the University of Swansea will validate the model in the SAIL dataset. Due to size of the training and validation datasets, we will use the same methods for internal and external validation as we don't expect a large degree of optimism.

# Sample Size for External Validation

Sample size calculations for external validation have not been formally calculated as, given the expected size of cohort, a sufficient amount of data should be available for precise estimates of model performance.

#### Statistical Software

Analysis and data preparation will be caried out using the software packages Python (v3.10.8) and Stata (v18).

#### Model Presentation

The resulting model equations will be reported in the resulting manuscript and will also be presented as an interactive web calculator to aid with dissemination and implementation of the model.

#### Discussion

This study aims to develop and validate a risk prediction model for RA in primary care. It will provide an opportunity to utilise large primary care datasets for both model development and validation as such can provide several benefits. The training data should enable a model to be generalisable to the intended use case of point of care in primary care. The proposed datasets should translate into a large sample size and thus allow for more stable model parameters. (29) The model will also be externally validated in two separate databases, with one being carried out by an independent group. This should provide a high level of validation and establish increased generalisability to UK primary care.

This study will, however, have limitations. Early analysis has suggested the possibility of poor coding of symptoms. Joint specific pathology appears to be poorly reported and may be more prevalent in free text notes, which we cannot access in the present study. Future work using natural language processing may provide a mechanism to address this and further increase the accuracy of future models. (30) Furthermore, we envisage missing data to be a significant issue, especially for continuous variables. However, we will have missing data strategies which aim to reduce the effects of this where possible. Finally, although the dataset is representative of primary care, coding practices can vary between GP practices and as such local performance of the model could vary. (31) Additionally, if a model was adopted this may further change coding practices and future retraining of a model may be required.

# References

- Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, et al. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med Princ Pract. 2019; 27(6): 501-507
- 2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. 2016; 388(10055):2023-38.
- 3. Scott IC, Whittle R, Bailey J, Twohig H, Hider SL, Mallen CD, et al. Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. The Lancet Regional Health Europe. 2022; 23.
- 4. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. 2016; 388(10055):2023-38.
- 5. Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, et al. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. Front Immunol. 2022; 13: 1051082
- 6. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006; 20(5):849-63.
- 7. van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010; 62(12):3537-46.
- Chilton F, Bradley E, Mitchell T. 'Lost time'. Patients with early inflammatory/rheumatoid arthritis and their experiences of delays in Primary Care. Musculoskeletal Care. 2021; 19(4):495-503.
- 9. Margham, T. Musculoskeletal disorders: time for joint action in primary care. British Journal of General Practice. 2011; 61(592): 657.
- 10. Stack RJ, van Tuyl LH, Sloots M, van de Stadt LA, Hoogland W, Maat B, et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. Rheumatology (Oxford). 2014; 53(9):1646-53.
- 11. Suter LG, Fraenkel L, Holmboe ES. What factors account for referral delays for patients with suspected rheumatoid arthritis? Arthritis Rheum. 2006; 55(2):300-5.
- 12. Galloway J, Ledingham J, Coalwood C, Oyebanjo S, Garnavos N. National Early Inflammatory Arthritis Audit (NEIAA). [internet]. 2022 [cited 2024 Mar 10]. Available from:
  - https://www.rheumatology.org.uk/Portals/0/Documents/Practice\_Quality/Audit/NEIA/2 022/NEIAA%20Fourth%20Annual%20Report\_FINAL\_11.01.23.pdf?ver=2023-01-11-165709-690

- 13. Lezcano-Valverde JM, Salazar F, León L, Toledano E, Jover JA, Fernandez-Gutierrez B, et al. Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach. Scientific Reports. 2017; 7(1):10189.
- 14. Yang C, Williams RD, Swerdel JN, Almeida JR, Brouwer ES, Burn E, et al. Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis. Semin Arthritis Rheum. 2022; 56:152050.
- 15. Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, et al. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technol Assess. 2018; 22(66):1-294.
- 16. de Rotte M, Pluijm SMF, de Jong PHP, Bulatović Ćalasan M, Wulffraat NM, Weel A, et al. Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis. PLoS One. 2018; 13(12):e0208534.
- 17. Scott IC, Seegobin SD, Steer S, Tan R, Forabosco P, Hinks A, et al. Predicting the Risk of Rheumatoid Arthritis and Its Age of Onset through Modelling Genetic Risk Variants with Smoking. PLOS Genetics. 2013; 9(9):e1003808.
- 18. van de Stadt LA, Witte Bi Fau Bos WH, Bos Wh Fau van Schaardenburg D, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis. 2013; 72(12):1920-6
- 19. van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 2008; 58(8):2241-7.
- 20. Muller S, Hider S, Machin A, Stack R, Hayward RA, Raza K, et al. Searching for a prodrome for rheumatoid arthritis in the primary care record: A case-control study in the clinical practice research datalink. Semin Arthritis Rheum. 2019; 48(5):815-20.
- 21. CPRD. CPRD Aurum Frequently asked questions (FAQs). [internet]. 2023 [cited 2024 Mar 10]. Available from: <a href="https://cprd.com/sites/default/files/2023-12/CPRD%20Aurum%20FAQs%20v2.4.pdf">https://cprd.com/sites/default/files/2023-12/CPRD%20Aurum%20FAQs%20v2.4.pdf</a>
- 22. CPRD. CPRD Aurum December 2023 Dataset. [internet]. 2023 [cited 2024 Mar 10]. Available from: <a href="https://cprd.com/cprd-aurum-december-2023-dataset">https://cprd.com/cprd-aurum-december-2023-dataset</a>
- 23. CPRD. CPRD GOLD December 2023 dataset [internet]. 2023 [cited 2024 Mar 10]. Available from: <a href="https://cprd.com/cprd-aurum-december-2023-dataset">https://cprd.com/cprd-aurum-december-2023-dataset</a>
- 24. Lyons J, Akbari A, Agrawal U, Harper G, Azcoaga-Lorenzo A, Bailey R, Rafferty J, et al. Protocol for the development of the Wales Multimorbidity e-Cohort (WMC): data

- sources and methods to construct a population-based research platform to investigate multimorbidity. BMJ Open. 2021; 11(1):e047101.
- 25. HDR UK. SAIL Databank [internet]. [date unknown] [cited 2024 Mar 10]. Available from: <a href="https://cprd.com/cprd-aurum-december-2023-dataset">https://cprd.com/cprd-aurum-december-2023-dataset</a>
- 26. Jones K. H, Ford D. V, Thompson S, Lyons R. A Profile of the SAIL Databank on the UK Secure Research Platform. International Journal of Population Data Science. 2020; 4(2).
- 27. CPRD. Defining your study population [internet]. 2023 [cited 2024 Mar 10]. Available from: <a href="https://cprd.com/defining-your-study-population">https://cprd.com/defining-your-study-population</a>
- 28. Wambua S, Crowe F, Thangaratinam S, O'Reilly D, McCowan C, Brophy S, et al. Protocol for development and validation of postpartum cardiovascular disease (CVD) risk prediction model incorporating reproductive and pregnancy-related candidate predictors. Diagnostic and Prognostic Research. 2022; 6(1):23.
- 29. Pate A, Emsley R, Sperrin M, Martin GP, van Staa T. Impact of sample size on the stability of risk scores from clinical prediction models: a case study in cardiovascular disease. Diagnostic and Prognostic Research. 2020; 4(1):14.
- 30. Ford E, Carroll J, Smith H, Daviers K, Koeling R, Petersen I, et al. What evidence is there for a delay in diagnostic coding of RA in UK general practice records? An observational study of free text. BMJ Open. 2016; 6(6):e010393.
- 31. Tai TW, Anandarajah S, Dhoul N, de Lusignan S. Variation in clinical coding lists in UK general practice: a barrier to consistent data entry? Inform Prim Care. 2007; 15(3):143-50.

# **Declarations**

# **Ethics Approval**

CPRD obtains annual research ethics approval from the UK's Health Research Authority Research Ethics Committee (East Midlands, Derby; reference no.05/MRE04/87) to receive and supply patient data for research. Therefore, no additional ethics approval is required for studies using CPRD data for research, subject to individual research protocols meeting CPRD data governance requirements. The use of CPRD data for the study was approved by the CPRD Independent Scientific Advisory Committee (reference no. 22\_002239). Individual patient data is available from CPRD with valid license.

## Patient Involvement

Development of this protocol as well as the ongoing prediction model is aided by monthly project meetings in which a patient partner, EI, participates and provides insight from a patient perspective.

# **Funding**

BH is funded by an MB-PhD studentship supported by The Kennedy Trust for Rheumatology Research [grant no. KENN 2021 04]. NIHR Research for Patient Benefit funds the Development and validation of Rheumatoid Arthritis Prediction moDel using primary care health records (RAPID), grant NIHR203621. AD is funded by a PhD studentship from the Applied Research Collaboration Northwest, in turn funded by the National Institute for Health Research (NIHR). KR, KN and NJA are supported by the NIHR Birmingham Biomedical Research Centre (BRC). This is independent research carried out at the NIHR BRC. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. CM is part funded by the NIHR ARC West Midlands and the NIHR School for Primary Care Research

## Conflict of Interest

JSC and KN are co-directors of DExtER operating division which is part of the University of Birmingham. DExtER operating division supports the extraction and preparing of healthcare data to support epidemiological analyses such as those seen in this article.